Medibank Pvt Ltd (ASX: MPL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Medibank Pvt Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $10.19 billion
P/E Ratio 20.67
Dividend Yield 4.49%
Shares Outstanding 2.75 billion
Earnings per share 0.179
Dividend per share 0.17
Year To Date Return 8.60%
Earnings Yield 4.84%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Medibank Pvt Ltd (ASX: MPL)
    Latest News

    A young man sits at his desk working on his laptop with a big smile on his face due to his ASX shares going up and in particular the Computershare share price
    Share Market News

    5 things to watch on the ASX 200 on Wednesday

    It looks set to be another good day for the ASX 200 index.

    Read more »

    A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
    Share Fallers

    Why Legend Mining, Medibank, Starpharma, and Weebit Nano shares are sinking

    These ASX shares are having a tough time on Tuesday.

    Read more »

    A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.
    Financial Shares

    Medibank share price trips on $250 million APRA hit

    The regulator has decided what actions need to be taken at Medibank after its major cyber breach.

    Read more »

    Stethoscope with a piggy bank and hundred dollar notes.
    Dividend Investing

    How do the dividends from Medibank shares compare to other ASX 200 blue chips?

    Is Medibank an overlooked ASX dividend share?

    Read more »

    a small child in a judo outfit with a green belt strikes a martial arts pose with his hand thrust forward and a cute smile on his face.
    Dividend Investing

    3 sectors to find defensive ASX dividend shares

    These are the sectors investors should look to for defensive income according to one top broker.

    Read more »

    A health professional wearing a stethoscope and scrubs shrugs with uncertainty.
    Share Market News

    Medibank or NIB shares? Only one is a buy according to Goldman Sachs

    Which private health insurer should you add to your portfolio?

    Read more »

    A businessman on a road raises his arms as dollar notes rain down on him.
    Dividend Investing

    How to invest $10,000 in ASX dividend shares in May

    Want to spend money to make money? Try these shares.

    Read more »

    Woman in pink shirt ticks checklist with red checkmarks
    Opinions

    6 criteria for picking quality stocks (and 3 ASX 200 shares that meet all of them right now)

    Here’s why these businesses could be strong performers in the current circumstances.

    Read more »

    Two healthcare workers, a male doctor in the background with a woman in scrubs in the foreground,, smile towards the camera against a plain backdrop.
    Healthcare Shares

    Is the Medibank share price a buy following the ASX 200 insurer's latest update?

    Does Medibank's update make it a buy or not?

    Read more »

    a hand of a man in a suit points a finger towards old fashioned brass scales that are not balanced in the foreground of the picture.
    Dividend Investing

    Perfect balance: 2 ASX 200 shares set to surge while paying dividends

    Two experts explain why these companies are well set to deliver both income and capital growth.

    Read more »

    A middle-aged woman sits in contemplation over a tablet device considering information about ASX shares and deep in thought.
    Investing Strategies

    This ASX 200 stock is 'one of the cheapest defensives' to buy right now

    Firetrail analysts reckon this stock is trading at an attractive entry point after an unfortunate incident last year.

    Read more »

    Stethoscope with a piggy bank and hundred dollar notes.
    Dividend Investing

    This ASX 200 share could pay a dividend yield of almost 7% by 2025

    This business could pay very healthy dividends in the next few years.

    Read more »

    Frequently Asked Questions

    Medibank Private was established by the Australian government in 1976 as a not-for-profit private health insurer. It converted into a for-profit entity in 2009 before listing on the ASX in November 2014.

    Yes, Medibank Private has paid dividends to shareholders every year since 2015. Typically, it pays an interim dividend in March and a final dividend in September, both fully franked.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    04 Sep 2024 $0.0940 100.00% Final 26 Sep 2024
    29 Feb 2024 $0.0720 100.00% Interim 20 Mar 2024
    13 Sep 2023 $0.0830 100.00% Final 05 Oct 2023
    02 Mar 2023 $0.0630 100.00% Interim 22 Mar 2023
    07 Sep 2022 $0.0730 100.00% Final 29 Sep 2022
    04 Mar 2022 $0.0610 100.00% Interim 24 Mar 2022
    08 Sep 2021 $0.0690 100.00% Final 30 Sep 2021
    03 Mar 2021 $0.0580 100.00% Interim 25 Mar 2021
    02 Sep 2020 $0.0630 100.00% Final 24 Sep 2020
    03 Mar 2020 $0.0570 100.00% Interim 26 Mar 2020
    04 Sep 2019 $0.0740 100.00% Final 26 Sep 2019
    05 Mar 2019 $0.0570 100.00% Interim 28 Mar 2019
    05 Sep 2018 $0.0720 100.00% Final 27 Sep 2018
    06 Mar 2018 $0.0550 100.00% Interim 28 Mar 2018
    06 Sep 2017 $0.0000 100.00% Final 28 Sep 2017
    07 Mar 2017 $0.0525 100.00% Interim 29 Mar 2017
    06 Sep 2016 $0.0600 100.00% Final 28 Sep 2016
    04 Mar 2016 $0.0500 100.00% Interim 29 Mar 2016

    MPL ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Medibank Pvt Ltd

    Previously owned by the Australian government, Medibank Private Ltd (ASX: MPL) is the largest health insurer in Australia.

    As of November 2022, its two brands, Medibank Private and ahm, provide cover to almost five million people.

    Medibank and Australia's fourth-largest health fund, NIB Holdings Limited (ASX: NIB), are the only health insurers listed on the ASX.

    In addition to private health insurance, the company provides life, pet, and travel insurance, as well as health insurance for overseas students and temporary overseas workers. The Medibank Health division provides healthcare services to businesses, governments, and communities across Australia and New Zealand.

    MPL Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    22 Nov 2024 $3.70 $-0.04 -1.07% 8,682,933 $3.75 $3.76 $3.70
    21 Nov 2024 $3.74 $0.01 0.27% 4,100,877 $3.77 $3.78 $3.72
    20 Nov 2024 $3.73 $-0.07 -1.84% 8,030,387 $3.79 $3.80 $3.72
    19 Nov 2024 $3.80 $0.00 0.00% 5,245,980 $3.79 $3.82 $3.76
    18 Nov 2024 $3.80 $-0.02 -0.52% 3,849,393 $3.79 $3.83 $3.77
    15 Nov 2024 $3.82 $0.08 2.14% 7,203,722 $3.75 $3.82 $3.74
    14 Nov 2024 $3.74 $0.04 1.08% 4,187,373 $3.72 $3.74 $3.70
    13 Nov 2024 $3.70 $-0.04 -1.07% 4,374,835 $3.70 $3.73 $3.69
    12 Nov 2024 $3.74 $0.05 1.36% 5,489,947 $3.71 $3.75 $3.69
    11 Nov 2024 $3.69 $-0.03 -0.81% 7,895,170 $3.72 $3.73 $3.69
    08 Nov 2024 $3.72 $0.04 1.09% 8,342,752 $3.70 $3.73 $3.68
    07 Nov 2024 $3.68 $0.03 0.82% 5,127,142 $3.68 $3.70 $3.65
    06 Nov 2024 $3.65 $0.05 1.39% 5,725,759 $3.61 $3.68 $3.58
    05 Nov 2024 $3.60 $-0.01 -0.28% 3,713,267 $3.59 $3.62 $3.58
    04 Nov 2024 $3.61 $0.06 1.69% 6,524,403 $3.61 $3.63 $3.56
    01 Nov 2024 $3.55 $-0.04 -1.11% 4,361,787 $3.57 $3.58 $3.53
    31 Oct 2024 $3.59 $-0.01 -0.28% 5,584,887 $3.60 $3.61 $3.55
    30 Oct 2024 $3.60 $-0.04 -1.10% 5,309,643 $3.63 $3.64 $3.59
    29 Oct 2024 $3.64 $0.00 0.00% 5,270,020 $3.64 $3.66 $3.62
    28 Oct 2024 $3.64 $-0.05 -1.36% 6,568,201 $3.69 $3.70 $3.64
    25 Oct 2024 $3.69 $0.01 0.27% 3,366,313 $3.68 $3.71 $3.68

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    02 Sep 2024 David Koczkar Expiry 260,942 $1,041,158
    As advised by the company. Lapsed,1,839,835 Rights
    02 Sep 2024 David Koczkar Buy 457,907 $1,827,048
    Conversion of securities.
    02 Sep 2024 David Koczkar Exercise 457,907 $1,827,048
    Conversion of securities. 1,381,928 Rights
    26 Aug 2024 Jay Weatherill Buy 5,100 $19,915
    On-market trade.
    26 Aug 2024 Michael (Mike) Wilkins Buy 100,000 $396,000
    On-market trade.
    26 Aug 2024 Kathryn Fagg Buy 32,750 $129,362
    On-market trade.
    26 Feb 2024 Linda Nicholls Buy 5,400 $19,710
    On-market trade.
    11 Dec 2023 David Koczkar Issued 653,088 $2,292,338
    Issue of securities. 2,100,777 Performance Rights

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Michael (Mike) John Wilkins Non-Executive DirectorNon-Executive Chairman May 2017
    Mr Wilkins has more than 30 years of experience in financial services, predominantly in Australia and Asia. He is a member of Investment and Capital and People Committee.
    Mrs Linda Bardo Nicholls Non-Executive Director Mar 2014
    Mrs Nicholls has more than 30 years of experience as a senior executive and director in banking, insurance and funds management in Australia, New Zealand and the United States. She is the Chair of the Investment and Capital Committee and also a member of Risk Management Committee.
    Ms Kathryn Joy Fagg Non-Executive Director Mar 2022
    Ms Fagg is a director and Chair with wide-ranging senior commercial and operational experience. She is a member of People Committee.
    Mr David Fagan Non-Executive Director Mar 2014
    Mr Fagan has practised as a commercial lawyer for over 40 years. During that time, he held a variety of leadership positions at Clayton Utz culminating in the role of Chief Executive Partner for 9 years. He is the Chair of the Risk Management Committee.
    Mr David Koczkar Chief Executive OfficerManaging Director May 2021
    Mr Koczkar has more than 25 years of strategy, innovation, commercial and operational experience across Australia, Asia and the UK, including previous work in the consulting and financial services industries.
    Mr Peter Dobie Everingham Non-Executive Director Mar 2022
    Mr Everingham has over 25 years of corporate experience and is highly respected in the digital sector, having held senior executive roles in that sector for 18 years. His senior leadership experience includes key roles at companies with a strong consumer and technology focus. He is a member of People and Investment and Capital Committee.
    Dr Tracey Leigh Batten Non-Executive Director Aug 2017
    Dr Batten has experience in the health services sector, with strong commercial, business and change leadership skills. She is the Chair of the People Committee and also a member of Risk Management Committee.
    Mr Gerard Dalbosco Non-Executive Director May 2021
    Mr Dalbosco held a number of senior leadership roles including Oceania Managing Partner and CEO; Asia Pacific Joint Deputy CEO and Managing Partner-Markets; Oceania Managing Partner-Transaction Advisory Services; and Melbourne Managing Partner. Prior to these roles Gerard advised organisations across a range of sectors in respect of merger and acquisitions advice, valuations, and strategic, commercial and financial due diligence. He is a member of Risk Management Committee.
    Mr Jay Wilson Weatherill Non-Executive Director Mar 2024
    Mr Weatherill has had a career in public office with expertise across a wide range of public policy areas including reform of social services. He is a member of Risk Management Committee.
    Ms Mei Ramsay Group General CounselCompany Secretary Mar 2011
    -
    Mei Ramsay Group General CounselCompany Secretary
    -
    Rob Read Group Lead Amplar Health
    -
    Milosh Milisavljevic Group Lead Chief Customer Officer
    -
    Mark Rogers Group Lead Chief Financial Officer & Group Strategy
    -
    Tom Exton Group Lead Chief Risk & Compliance Officer
    -
    Felicia Trewin Group Lead Data & Technology
    -
    Rob Deeming Group Lead Digital & Ventures
    -
    Kylie Bishop Group Lead People Spaces & Sustainability
    -
    Meaghan Telford Group Lead Policy Advocacy & Reputation
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 897,801,743 32.60%
    J P Morgan Nominees Australia Pty Limited 542,208,525 19.69%
    Citicorp Nominees Pty Limited 320,377,977 11.63%
    National Nominees Limited 81,375,680 2.95%
    BNP Paribas Nominees Pty Ltd <Agency Lending A/C> 71,271,047 2.59%
    BNP Paribas Noms Pty Ltd 46,314,124 1.68%
    Citicorp Nominees Pty Limited <Colonial First State Inv A/C> 21,450,620 0.78%
    HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> 20,002,248 0.73%
    HSBC Custody Nominees (Australia) Limited A/C 2 8,980,884 0.33%
    BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> 7,590,106 0.28%
    HSBC Custody Nominees (Australia) Limited i 7,343,069 0.27%
    Netwealth Investments Limited <Wrap Services A/C> 6,630,695 0.24%
    IOOF Investment Services Limited <Ips Superfund A/C> 5,169,307 0.19%
    UBS Nominees Pty Ltd 4,975,089 0.18%
    Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> 4,961,790 0.18%
    IOOF Investment Services Limited <Iisl Nal Isma 2 A/C> 3,786,900 0.14%
    Bond Street Custodians Limited <Cockej - F01832 A/C> 3,784,143 0.14%
    Ioof Investment Services Limited <Ioof Idps A/C> 3,745,418 0.14%
    Netwealth Investments Limited <Super Services A/C> 3,279,571 0.12%
    Solium Nominees (Australia) Pty Ltd <Vsa A/C> 3,221,313 0.12%

    Profile

    since

    Note